Cellular and molecular mechanisms of action of bisphosphonates
- PMID: 10898340
- DOI: 10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.3.co;2-c
Cellular and molecular mechanisms of action of bisphosphonates
Abstract
Background: Bisphosphonates currently are the most important class of antiresorptive agents used in the treatment of metabolic bone diseases, including tumor-associated osteolysis and hypercalcemia, Paget's disease, and osteoporosis. These compounds have high affinity for calcium and therefore target to bone mineral, where they appear to be internalized selectively by bone-resorbing osteoclasts and inhibit osteoclast function.
Methods: This article reviews the pharmacology of bisphosphonates and the relation between the chemical structure of bisphosphonates and antiresorptive potency, and describes recent new discoveries of their molecular mechanisms of action in osteoclasts.
Results: Bisphosphonates can be grouped into two pharmacologic classes with distinct molecular mechanisms of action. Nitrogen-containing bisphosphonates (the most potent class) act by inhibiting the mevalonate pathway in osteoclasts, thereby preventing prenylation of small GTPase signaling proteins required for osteoclast function. Bisphosphonates that lack a nitrogen in the chemical structure do not inhibit protein prenylation and have a different mode of action that may involve the formation of cytotoxic metabolites in osteoclasts or inhibition of protein tyrosine phosphatases.
Conclusions: Bisphosphonates are highly effective inhibitors of bone resorption that selectively affect osteoclasts. After more than 30 years of clinical use, their molecular mechanisms of action are only just becoming clear.
Similar articles
-
New insights into the molecular mechanisms of action of bisphosphonates.Curr Pharm Des. 2003;9(32):2643-58. doi: 10.2174/1381612033453640. Curr Pharm Des. 2003. PMID: 14529538 Review.
-
Molecular mechanisms of action of bisphosphonates: current status.Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6222s-6230s. doi: 10.1158/1078-0432.CCR-06-0843. Clin Cancer Res. 2006. PMID: 17062705 Review.
-
Bisphosphonates: from the laboratory to the clinic and back again.Bone. 1999 Jul;25(1):97-106. doi: 10.1016/s8756-3282(99)00116-7. Bone. 1999. PMID: 10423031 Review.
-
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.J Bone Miner Res. 1998 Apr;13(4):581-9. doi: 10.1359/jbmr.1998.13.4.581. J Bone Miner Res. 1998. PMID: 9556058
-
Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.Curr Pharm Des. 2010;16(27):2950-60. doi: 10.2174/138161210793563635. Curr Pharm Des. 2010. PMID: 20722616 Review.
Cited by
-
Zoledrinic Acid Induces Steoblastic Differentiation of Mesenchymal Stem Cells without Change in Hypomethylation Status of OSTERIX Promoter.Cell J. 2012 Summer;14(2):90-7. Epub 2012 Aug 31. Cell J. 2012. PMID: 23508196 Free PMC article.
-
The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.Lasers Med Sci. 2017 Jan;32(1):229-242. doi: 10.1007/s10103-016-2056-y. Epub 2016 Aug 19. Lasers Med Sci. 2017. PMID: 27539464 Review.
-
Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review.Acta Biomater. 2012 Apr;8(4):1401-21. doi: 10.1016/j.actbio.2011.11.017. Epub 2011 Nov 20. Acta Biomater. 2012. PMID: 22127225 Free PMC article. Review.
-
Medication-related osteonecrosis of the jaw: a dentist's nightmare.BMJ Case Rep. 2016 Apr 6;2016:bcr2016214626. doi: 10.1136/bcr-2016-214626. BMJ Case Rep. 2016. PMID: 27053542 Free PMC article.
-
Pathophysiology and therapeutic advances in myeloma bone disease.Chronic Dis Transl Med. 2022 Jul 4;8(4):264-270. doi: 10.1002/cdt3.35. eCollection 2022 Dec. Chronic Dis Transl Med. 2022. PMID: 36420171 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources